INMB (INmune Bio) Operating Cash Flow per Share : $-1.55 (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Operating Cash Flow per Share?

INmune Bio's operating cash flow per share for the three months ended in Mar. 2025 was $-0.30. INmune Bio's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.55.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 1.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for INmune Bio's Operating Cash Flow per Share or its related term are showing as below:

INMB' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -165.5 Med: -73.35 Max: 3.7
Current: 1.8

During the past 9 years, INmune Bio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 3.70% per year. The lowest was -165.50% per year. And the median was -73.35% per year.

INMB's 3-Year OCF Growth Rate is ranked worse than
58.83% of 1217 companies
in the Biotechnology industry
Industry Median: 9.3 vs INMB: 1.80

INmune Bio Operating Cash Flow per Share Historical Data

The historical data trend for INmune Bio's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Operating Cash Flow per Share Chart

INmune Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.75

-1.77

-1.27

-0.67

-1.67

INmune Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.42	-0.41	-0.35	-0.50	-0.30

Competitive Comparison of INmune Bio's Operating Cash Flow per Share

For the Biotechnology subindustry, INmune Bio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where INmune Bio's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

INmune Bio Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

INmune Bio's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-33.361	/	19.944
	=	-1.67

INmune Bio's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-6.824	/	22.496
	=	-0.30

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.55

INmune Bio Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of INmune Bio's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

INmune Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432

Website

https://www.inmunebio.com

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Executives

David J Moss	10 percent owner, officer: CFO, Treasurer & Secretary	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi	director, 10 percent owner, officer: President & CEO	476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Scott Juda	director	325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Mark William Lowdell	10 percent owner, officer: Chief Scientific Officer	THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Timothy J Schroeder	director	2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
Linda F Powers	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei	director	10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen	director	P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini	director	C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc	10 percent owner	465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski	director	241 WEST PALM AVENUE, MONROVIA CA 91016